Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00035841 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of TLK286 in Metastatic Breast Cancer
A Phase 2 study of Breast Neoplasms, sponsored by Telik.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 3
- Study locations
NCT00035841: Completed Phase 2 study of Breast Neoplasms, sponsored by Telik.
NCT00035841 is a Phase 2 study of Breast Neoplasms that has completed, run by Telik. The registered enrollment target is 60 participants, below the 568-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (89% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00035841, a Phase 2 study of Breast Neoplasms, has completed, sponsored by Telik.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to determine the effectiveness of TLK286 in treatment of metastatic breast cancer.
Conditions Studied
Interventions
- DRUG TLK286
Study Locations (3)
Arizona
- Arizona Cancer Center - Tucson
Indiana
- Indiana University Medical Center - Indianapolis
Ohio
- Cleveland Clinic Taussig Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2002-04 |
| Est. Completion | 2004-07 |
| Phase | Phase 2 |
What the finished NCT00035841 record still lists
NCT00035841 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 568-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Breast Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which TLK286 is the first listed.
NCT00035841 reports a single indexed study location in Arizona, Indiana, Ohio.
Frequently Asked Questions
What is clinical trial NCT00035841 about?
NCT00035841 is a clinical study titled "Phase 2 Study of TLK286 in Metastatic Breast Cancer". The purpose of this study is to determine the effectiveness of TLK286 in treatment of metastatic breast cancer.
What is the current status of trial NCT00035841?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2002-04. Estimated completion is 2004-07.
What conditions does trial NCT00035841 study?
This clinical trial studies the following conditions: Breast Neoplasms.
What interventions are being tested in trial NCT00035841?
The interventions under investigation include: TLK286 (DRUG).
Who is sponsoring clinical trial NCT00035841?
This trial is sponsored by Telik, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00035841 being conducted?
This trial has 3 study locations across Arizona, Indiana, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00035841's enrollment target sits among peer trials
60 71st of 97 higher than 26 of 97 other Breast Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
RECRUITING · Phase 2
-
Tirzepatide Weight Loss for MRD+ Early Breast Cancer
RECRUITING · Phase 2
-
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
RECRUITING · Phase 2
-
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
RECRUITING · Phase 2
-
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia